Amanta Healthcare IPO Price: ₹120 to ₹126 per share
IPO Dates: 1st September 2025 – 3rd September 2025
Company Overview
Amanta Healthcare Limited, incorporated in December 1994, is a pharmaceutical company specializing in the development, manufacturing, and marketing of sterile liquid products, primarily parenteral products. These products are packaged in plastic containers using advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM). In addition to pharmaceuticals, the company is also engaged in the production of medical devices.
Originally established as Marck Parenterals (India) Ltd in Ahmedabad, Gujarat, the company underwent name changes in line with its evolving operations—becoming Marck Biosciences Ltd in 2005 and finally Amanta Healthcare Ltd in June 2014.
Product Portfolio
The company has a diversified product base, covering six therapeutic segments:
- Fluid therapy (IV fluids and formulations)
- Diluents
- Ophthalmic solutions
- Respiratory care products
- Irrigation solutions
- Medical devices (including first-aid solutions and eye lubricants)
Its products are manufactured in both Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs) formats. In terms of packaging, the company offers a wide range of closure systems—including nipple head, twist-off, leur-lock, and screw types—with container fill volumes ranging from 2 ml to 1,000 ml.
Currently, Amanta manufactures over 45 generic products, marketed under its own brands in India through a strong network of ~320 distributors and stockists.
Business Operations
Amanta Healthcare markets its products through three business units:
- National Sales – catering to hospitals, nursing homes, and healthcare providers in India.
- International Sales – exporting branded products to regulated and semi-regulated markets.
- Product Partnering – manufacturing for Indian and global pharmaceutical companies, including loan licensing arrangements.
As of FY 2025, the company’s products are registered in 19 countries and exported to 21 countries, including markets in Africa, Latin America, the UK, and other regions. The company’s portfolio of 47 products is registered across 120 international jurisdictions, ensuring wide compliance with global regulatory requirements.
Manufacturing Capabilities
Amanta Healthcare’s state-of-the-art facility at Hariyala, District Kheda, Gujarat, is spread over 66,852 sq. meters and equipped with advanced manufacturing lines:
- 4 LVP manufacturing lines – including 2 conventional single-port container lines (ABFS) and 2 SteriPort lines (ISBM).
- 3 SVP manufacturing lines – including 2 ABFS lines and 1 conventional three-piece container filling line.
The facility is supported by a Formulation and Development (F&D) unit and a quality control laboratory.
Certifications and Compliance
The company’s facilities hold multiple certifications, including:
- ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, and ISO 45001:2018.
- GMP certifications from the FDA, Gujarat, in line with WHO guidelines.
- GMP accreditations from Cambodia, Sudan, Philippines, and Zimbabwe.
- DNV certification for exports of medical device products.
These accreditations allow the company to manufacture and export products in various sterile liquid forms, including antibiotics, antifungals, diuretics, quinolones, ophthalmic, and respiratory products.
Competitive Strengths
Amanta Healthcare’s market positioning is supported by the following strengths:
- Established track record as a manufacturer of sterile pharmaceutical formulations.
- Diverse product portfolio across multiple therapeutic segments and medical devices.
- Large-scale manufacturing capacity with advanced technologies.
- Strong domestic and international distribution network.
- Experienced management team backed by a skilled and diverse workforce.
- Regulatory-compliant facilities catering to both developed and emerging markets.
Bidding Starts In
Amanta Healthcare IPO Specifics:
| IPO Date | September 1, 2025 to September 3, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹120 to ₹126 per share |
| Lot Size | 119 Shares |
| Total Issue Size | 1,00,00,000 shares (aggregating up to ₹126.00 Cr) |
| Fresh Issue | 1,00,00,000 shares (aggregating up to ₹126.00 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 2,88,29,351 shares |
| Share Holding Post Issue | 3,88,29,351 shares |
Amanta Healthcare IPO Timetable (Important Dates)
| IPO Open Date | Monday, September 1 2025 |
| IPO Close Date | Wednesday, September 3 2025 |
| Basis of Allotment | Thursday, September 4 2025 |
| Initiation of Refunds | Monday, September 8 2025 |
| Credit of Shares to Demat | Monday, September 8 2025 |
| Listing Date | Tuesday, September 2 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on September 3, 2025 |
Amanta Healthcare IPO Lot Size
Bidders have the opportunity to bid for a minimum of 119 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 119 | ₹14,994 |
| Retail (Max) | 13 | 1,547 | ₹1,94,922 |
| S-HNI (Min) | 14 | 1,666 | ₹2,09,916 |
| S-HNI (Max) | 66 | 7,854 | ₹9,89,604 |
| B-HNI (Min) | 67 | 7,973 | ₹10,04,598 |
Amanta Healthcare IPO Reservation
| QIB Shares Offered | Not more than 50% of the Net offer |
| Retail Shares Offered | Not less than 35% of the Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Offer |
Amanta Healthcare Limited IPO Financial Information
| Period Ended | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 |
|---|---|---|---|
| Assets | 374.06 | 352.12 | 381.76 |
| Revenue | 262.70 | 281.61 | 276.09 |
| Profit After Tax | -2.11 | 3.63 | 10.50 |
| EBITDA | 56.31 | 58.76 | 61.05 |
| Net Worth | 62.88 | 66.29 | 96.39 |
| Reserves & Surplus | 36.05 | 39.46 | 67.56 |
| Total Borrowing | 215.66 | 205.23 | 195 |
Key Performance Indicator – Amanta Healthcare IPO
| KPI | Values |
|---|---|
| Market Cap | ₹489.25 Cr |
| EPS | ₹3.64 |
| P/E (x) | 34.59 |
| ROE | 12.42% |
| ROCE | 13.72% |
| PAT Margin | 3.86% |
| RoNW | 10.89% |
| Debt/Equity | 2.02 |
Objects of the Issue:
Amanta Healthcare Limited proposes to utilize the net proceeds from its Initial Public Offering (IPO) for the following purposes:
- Funding Capital Expenditure for SteriPort Manufacturing Line: An amount of ₹70.00 crore will be allocated towards civil construction work and the purchase of equipment, plant, and machinery for setting up a new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat.
- Funding Capital Expenditure for SVP Manufacturing Line: ₹30.13 crore will be utilized for civil construction work and the purchase of equipment, plant, and machinery for establishing a new manufacturing line for SVP at Hariyala, Kheda, Gujarat.
- General Corporate Purposes: The balance of the proceeds will be used for general corporate activities, which may include administrative expenses, brand building, and other strategic initiatives to support business growth.
Prospectus Links:
Prospectus: Official documents that provide detailed information about the IPO and the company.
